Practical Approaches to the Use of Lenalidomide in Multiple Myeloma: A Canadian Consensus

Table 6

The effect of Len/Dex treatment according to prior response to thalidomide. Adapted from Wang et al. [19].

	Thalidomide sensitive^1			Thalidomide relapsed^2			Thalidomide resistant3
	Len/Dex	Placebo/Dex	𝑃	Len/Dex	Placebo/Dex	𝑃	Len/Dex	Placebo/Dex	𝑃
Overall response rates (PR or better) %	64.8	17.1	<0.001	41.9	5.9	<0.01	50	20.8	0.042
Response duration, mo (95% CI)	13.4; (7.0 to NE)	3.2; (2.3 to NE)	0.009	8.8; (5.3 to NE)	NE; (8.6 to NE)	0.77	NE; (6.0 to NE)	NE; (6.0 to NE)	0.22
Median PFS, mo (95% CI)	9.3; (5.6 to 18.0)	4.6; (3.9 to 4.7)	<0.001	7.8; (5.2 to 11.1)	3.7; (2.8 to 6.5)	0.002	7.0; (4.9 to 16.9)	3.7; (2.1 to 8.4)	0.013

¹Sensitive: patients with stable disease or better who did not progress while on thalidomide.
²Relapsed: patients with stable disease or better who progressed while on thalidomide.
³Resistant: patients who progressed on thalidomide but never responded to thalidomide.
Len/Dex: lenalidomide combined with dexamethasone; PR: partial response; PFS: progression-free survival; NE: not estimable.